These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33478482)

  • 1. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study.
    Lopresti AL; Smith SJ; Rea A; Michel S
    BMC Complement Med Ther; 2021 Jan; 21(1):40. PubMed ID: 33478482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial.
    Ghoshal UC; Srivastava D; Misra A; Ghoshal U
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):281-9. PubMed ID: 26731696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A poly-herbal blend (Herbagut®) on adults presenting with gastrointestinal complaints: a randomised, double-blind, placebo-controlled study.
    Lopresti AL; Gupta H; Smith SJ
    BMC Complement Altern Med; 2018 Mar; 18(1):98. PubMed ID: 29554961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
    Zhuang X; Tian Z; Luo M; Xiong L
    BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
    El-Salhy M; Hatlebakk JG; Gilja OH; Bråthen Kristoffersen A; Hausken T
    Gut; 2020 May; 69(5):859-867. PubMed ID: 31852769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI; Christensen AH; Lo BZS; Browne PD; Günther S; Hansen LH; Petersen AM
    Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of 'Zesy002' kiwifruit (
    Eady SL; Wallace AJ; Butts CA; Hedderley D; Drummond L; Ansell J; Gearry RB
    J Nutr Sci; 2019; 8():e18. PubMed ID: 31080591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.
    Fodor AA; Pimentel M; Chey WD; Lembo A; Golden PL; Israel RJ; Carroll IM
    Gut Microbes; 2019; 10(1):22-33. PubMed ID: 29708822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.
    Francavilla R; Piccolo M; Francavilla A; Polimeno L; Semeraro F; Cristofori F; Castellaneta S; Barone M; Indrio F; Gobbetti M; De Angelis M
    J Clin Gastroenterol; 2019 Mar; 53(3):e117-e125. PubMed ID: 29688915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome.
    Yang M; Zhang L; Hong G; Li Y; Li G; Qian W; Xiong H; Bai T; Song J; Hou X
    J Gastroenterol Hepatol; 2020 May; 35(5):795-805. PubMed ID: 31674052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
    Guglielmetti S; Mora D; Gschwender M; Popp K
    Aliment Pharmacol Ther; 2011 May; 33(10):1123-32. PubMed ID: 21418261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Lahtinen P; Jalanka J; Hartikainen A; Mattila E; Hillilä M; Punkkinen J; Koskenpato J; Anttila VJ; Tillonen J; Satokari R; Arkkila P
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1321-1331. PubMed ID: 32343000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study.
    Iribarren C; Törnblom H; Aziz I; Magnusson MK; Sundin J; Vigsnaes LK; Amundsen ID; McConnell B; Seitzberg D; Öhman L; Simrén M
    Neurogastroenterol Motil; 2020 Oct; 32(10):e13920. PubMed ID: 32536023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small intestinal bacterial overgrowth in patients with lower gastrointestinal symptoms and a history of previous abdominal surgery.
    Petrone P; Sarkisyan G; Fernández M; Coloma E; Akopian G; Ortega A; Kaufman HS
    Arch Surg; 2011 Apr; 146(4):444-7. PubMed ID: 21502453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study.
    Bustos Fernández LM; Man F; Lasa JS
    Dig Dis; 2023; 41(5):798-809. PubMed ID: 36630947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study.
    Azpiroz F; Dubray C; Bernalier-Donadille A; Cardot JM; Accarino A; Serra J; Wagner A; Respondek F; Dapoigny M
    Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27477485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.